checkAd

     172  0 Kommentare Summit Therapeutics Appoints Dr. Mahkam (“Maky”) Zanganeh as Chief Operating Officer - Seite 2

    About Summit Therapeutics

    Summit Therapeutics, empowered by its Discuva Platform, the Company’s innovative antibiotic discovery engine, supported by BARDA and Carb-X funding, intends to be the leader in patient- and physician-friendly, paradigm-shifting antibiotic innovation. Our new mechanism antibiotics are designed to become the patient-friendly, new-era standard of care, by working in harmony with the human microbiome to treat prospective patients suffering from infectious disease, initially focusing on Clostridioides difficile infections (“CDI”) which is estimated to impact over 3 million patients worldwide annually. Commercialization of ridinilazole for the treatment and the reduction of recurrence of CDI is subject to regulatory approvals. The overriding objective of Summit Therapeutics is to create value for patients, hospital infectious disease caregivers, community-based infectious disease healthcare providers, as well as healthcare payors around the world.  Currently, Summit’s lead product candidate, ridinilazole, is engaged in two global Phase III trials, Ri-CoDIFy 1 & 2, each enrolling 680 patients vs. the standard of care (Vancomycin) for the treatment and reduction of recurrence of C. difficile infections.

    Summit’s vision and mission is to extend our pipeline through the development of new mechanism, narrow spectrum, microbiome-sparing antibiotics targeting C. difficile, Gram-negative Enterobacteriaceae, such as Escherichia coli and Klebsiella pneumoniae, and other bacterial infections with high unmet medical need.

    For more information, visit www.summittxinc.com and follow us on Twitter @summitplc. For more information on the Company’s Discuva Platform, visit https://www.summittxinc.com/our-science/discuva-platform.

    Contract Summit Investor Relations:

    Dave Gancarz

    Vice President, Investor Relations & Corporate Strategy

    david.gancarz@summitplc.com

    General Inquiries: 

    investors@summitplc.com

    Summit Forward-looking Statements

    Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company’s product candidates, the therapeutic potential of the Company’s product candidates, the potential commercialization of the Company’s product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the impact of the COVID-19 pandemic on the Company’s operations and clinical trials and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, global public health crises, including the coronavirus COVID-19 outbreak, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of filings that the Company makes with the Securities and Exchange Commission. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.

    Seite 2 von 3



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Summit Therapeutics Appoints Dr. Mahkam (“Maky”) Zanganeh as Chief Operating Officer - Seite 2 Summit Therapeutics Inc.(‘Summit,’ the ‘Company,’ or the ‘Group’) Summit Therapeutics Appoints Dr. Mahkam (“Maky”) Zanganeh as Chief Operating Officer Cambridge, MA, November 23, 2020 – Summit Therapeutics Inc. (NASDAQ: SMMT) announces that Dr. …

    Schreibe Deinen Kommentar

    Disclaimer